AccuStem Acquires MSC Lung Cancer Screening Test
Deal News | Mar 18, 2025 | Globenewswire
AccuStem Sciences, Inc., a clinical stage diagnostics company, has acquired the proprietary microRNA Signature Classifier (MSC) test for lung cancer screening. The MSC test, developed by researchers at Istituto Nazionale Tumori, enhances the diagnostic performance of low-dose computed tomography (LDCT) in screening lung nodules by evaluating 24 micro RNAs. The acquisition is aimed at the strategic commercialization of the MSC test in the US by 2026, with AccuStem issuing 3,750,000 common shares to certain creditors and interest holders as consideration. The MSC test shows potential to provide more accurate diagnoses, reduce false positives, and lower healthcare costs, promising significant improvements in patient outcomes. AccuStem plans to leverage its experience in commercializing novel diagnostics to bring MSC to as many patients as possible.
Sectors
- Biotechnology
- Healthcare Diagnostics
- Healthcare Services
Geography
- United States – AccuStem Sciences plans to launch the MSC cancer screening test in the US, making it a primary geography for the company’s commercialization strategy.
- United Kingdom – AccuStem Sciences is partly based in the UK, as indicated by the London location in its press release.
- Italy – The MSC test was developed by researchers at the Istituto Nazionale Tumori in Milan, highlighting Italy's role in the test's origin.
Industry
- Biotechnology – The acquisition involves a proprietary lung cancer screening test, a product of biotechnology and clinical diagnostics innovation.
- Healthcare Diagnostics – AccuStem Sciences specializes in diagnostics technologies, particularly for cancer, aligning it with the healthcare diagnostics industry.
- Healthcare Services – The outcome of this acquisition impacts healthcare services by potentially providing more accurate cancer diagnostics and patient management strategies.
Financials
- 3,750,000 – Number of AccuStem common shares issued as part of the consideration for the MSC test acquisition.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AccuStem Sciences, Inc. | Acquirer | Company | A clinical stage diagnostics company focusing on cancer diagnostics and patient outcomes. |
| Istituto Nazionale Tumori | Research Institute | Company | An Italian research institute where the MSC test was developed. |
| Wendy Blosser | Chief Executive Officer | Person | CEO of AccuStem Sciences, leading the strategic acquisition. |
| Mattia Boeri, PhD | Researcher | Person | One of the developers of the MSC test at the Istituto Nazionale Tumori. |
| Ugo Pastorino, MD | Researcher | Person | Co-developer of the MSC test at the Istituto Nazionale Tumori. |
| Gabriella Sozzi, PhD | Researcher and Director of Research Department | Person | Contributed to the MSC test development and serves as Director at INT Milan. |